Ascendiant Capital initiates Galectin Therapeutics at Buy

Ascendiant Capital Markets starts Galectin Therapeutics (GALT +6.8%) at Buy, calling the company "an intriguing speculative small cap investment story."

Price target is $13, representing an 18% upside from Friday's close.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs